Recent Company News

• 09:27 AM ET Mar 23, 2026
  

  Trinity Biotech announces clinical results for its enhanced EpiCapture prostate cancer test ($0.64, 0.00)

• 08:37 AM ET Mar 18, 2026
  

  Trinity Biotech announces collaboration with University at Buffalo to commercialize novel biomarkers for Sjögren's syndrome ($0.74, 0.00)

• 07:47 AM ET Mar 10, 2026
  

  Trinity Biotech guides Q4 revenue $11.5M-12.5M vs year-ago $15.9M ($0.70, 0.00)

• 09:04 AM ET Feb 25, 2026
  

  Trinity Biotech Secures enters $25M SEPA with Yorkville in support of growth initiatives; provides business update ($0.75, 0.00)

• 01:31 PM ET Feb 10, 2026
  

  Trinity Biotech secures regulatory approval for commencement of upstream manufacturing activities of Uni-Gold HIV rapid test ($0.91, +0.11)

• 08:53 AM ET Dec 23, 2025
  

  Trinity Biotech announces financing transactions with Perceptive Advisors ($0.89, 0.00)

• 07:37 AM ET Dec 23, 2025
  

  Follow-up: Trinity Biotech reports preliminary Q3 results, updates on pipeline developments, announces interim CFO transition ($0.89, 0.00)

• 07:33 AM ET Dec 23, 2025
  

  Trinity Biotech announces order for 9M TrinScreen HIV tests ($0.89, 0.00)

• 09:18 AM ET Dec 15, 2025
  

  Trinity Biotech expands global rollout of high-capacity column system for FDA-cleared HbA1c testing solution after securing regulatory clearances ($1.07, 0.00)

• 01:47 PM ET Dec 05, 2025
  

  StreetAccount Activist Summary: Week of 1-Dec